Posts by: Magdalena Kegel

Magdalena Kegel

Magdalena is a writer with a passion for bridging the gap between the people performing research, and those who want or need to understand it. She writes about medical science and drug discovery. She holds an MS in Pharmaceutical Bioscience and a PhD — spanning the fields of psychiatry, immunology, and neuropharmacology — from Karolinska Institutet in Sweden.

December 15, 2017December 15, 2017

FDA Reviews Application for Keytruda in Mediastinal B-cell Lymphoma

News

The U.S. Food and Drug Administration (FDA) agreed to review Merck’s application to add relapsed or refractory primary mediastinal large B-cell lymphoma (PMBCL) to the list of cancers treated with ... Read more

December 7, 2017

Polatuzumab Vedotin Addition Makes Stark Difference for DLBCL Patients, Studies Show

News

Adding the investigational treatment polatuzumab vedotin to a therapy of Bendeka (bendamustine) and Rituxan (rituximab) made patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) respond better to the ... Read more

November 21, 2017November 21, 2017

EU Approves Tasigna for Certain Children with CML

News

The European Commission has approved Novartis’ Tasigna (nilotinib) for the treatment of children with a specific type of chronic myeloid leukemia (CML). The treatment is now approved for both newly ... Read more

November 20, 2017November 20, 2017

FDA Approves Gazyva-Chemo Combo for Advanced Follicular Lymphoma

News

The U.S. Food and Drug Administration (FDA) has approved Roche’s Gazyva (obinutuzumab) in combination with chemotherapy as a first-line treatment for patients with advanced follicular lymphoma. The company said its ... Read more

November 16, 2017November 17, 2017

Takeda to Showcase Adcetris as First-line Therapy in Hodgkin’s Lymphoma at ASH Meeting

News

Takeda Pharmaceutical will present new data on Adcetris (brentuximab vedotin) as first-line therapy for advanced Hodgkin’s lymphoma at the 59th American Society of Hematology (ASH) Annual Meeting, set for Dec. 9-12 ... Read more

November 15, 2017November 15, 2017

EMA Urges European Commission to Approve Takeda’s Adcetris as Therapy for CTCL

News

European regulators have endorsed the use of Takeda‘s Adcetris (brentuximab vedotin) to treat a specific type of cutaneous T-cell lymphoma (CTCL). The Brussels-based Committee for Medicinal Products for Human Use ... Read more

November 9, 2017November 9, 2017

Seattle Genetics Asks FDA to Accept Adcetris as Treatment for Hodgkin’s Lymphoma

News

Seattle Genetics has asked the U.S. Food and Drug Administration (FDA) to expand the label for Adcetris (brentuximab vedotin) to be used in combination with chemotherapy as a first-line treatment ... Read more

November 8, 2017

Novartis Files for Approval of Kymriah for Two Blood Cancers in the EU

News

Novartis continues the process of making Kymriah (tisagenlecleucel) commercially available outside the U.S., now by applying with the European Medicines Agency (EMA) to approve the treatment for two types of ... Read more

November 2, 2017

Novartis Asks FDA to Approve Kymriah for Difficult-to-treat DLBCL

News

Novartis has asked U.S. regulators to expand their approval of Kymriah (tisagenlecleucel) to include the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma, or DLBCL. The Food ... Read more

October 17, 2017October 17, 2017

Primary Care Programs for Cancer Survivors Are Still Lacking, Report Reveals

News

Primary care is not set up to meet the specific healthcare needs of cancer survivors, according to a study by researchers at Rutgers University. The study illustrates how efforts to ... Read more